<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998101</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0816</org_study_id>
    <secondary_id>P30CA016086</secondary_id>
    <secondary_id>CDR0000656960</secondary_id>
    <nct_id>NCT00998101</nct_id>
  </id_info>
  <brief_title>Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy</brief_title>
  <official_title>A Phase II Trial of Carboplatin, Ixabepilone and Cetuximab in Chemotherapy Naive Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and ixabepilone, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as cetuximab, can block cancer growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry cancer-killing substances to them. Giving chemotherapy together with&#xD;
      monoclonal antibodies may be a better way to block cancer growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving carboplatin and&#xD;
      ixabepilone together with cetuximab works in treating patients with stage III or stage IV&#xD;
      non-small cell lung cancer previously untreated with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To estimate the disease-control rate in patients with advanced chemotherapy-naive&#xD;
           non-small cell lung cancer after 2 courses of carboplatin, ixabepilone, and cetuximab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To estimate the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  To estimate the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  To estimate the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  To determine the potential predictive marker of efficacy of ixabepilone and cetuximab.&#xD;
           (exploratory)&#xD;
&#xD;
        -  To investigate the prevalence of cetuximab IgE antibody, and the rate of cetuximab&#xD;
           hypersensitivity reactions in patients without evidence of cetuximab IgE antibodies.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive carboplatin IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and&#xD;
      cetuximab IV over 1-2 hours on days 1, 8 and 15. Treatment repeats every 21 days for up to&#xD;
      2-4 courses in the absence of disease progression or unacceptable toxicity. Treatment&#xD;
      modifications may apply according to response.&#xD;
&#xD;
      Tumor tissue and blood samples are collected for further analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was withdrawn due issuses related to the science&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-control rate after 2 courses of carboplatin, cetuximab, and ixabepilone</measure>
    <time_frame>42 days</time_frame>
    <description>Disease control rate will be defined as patients experiencing a complete or partial response or stable disease (radiographic response) measured by RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Radigoraphic response of measurable disease will be assessed using RECIST critera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Radigoraphic response of measurable disease will be assessed using RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events will be assessed (graded) using CTCAE criteria</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes</description>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC=6 Day 1 of treatment over 30 minutes every 21 days</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>30 mg/m2 , Day 1 over 3 hours every 21 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Chemotherapy-naive&#xD;
&#xD;
               -  Stage IIIB disease not amenable to surgery with pleural effusion, pericardial&#xD;
                  effusion, or not a candidate for chemoradiotherapy&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  Must have pathology block or unstained slides from initial or subsequent diagnosis&#xD;
&#xD;
               -  Diagnosis made via a core biopsy (not a fine-needle aspirate) required&#xD;
&#xD;
          -  Measurable disease as defined by RECIST guidelines&#xD;
&#xD;
               -  For patient who received prior radiotherapy, evaluable disease must be outside of&#xD;
                  the radiation field, or have new lesions that developed within the radiation&#xD;
                  field&#xD;
&#xD;
          -  Brain metastasis allowed provided it has been treated and determined to be controlled&#xD;
             by the treating physician&#xD;
&#xD;
          -  No IgE cetuximab antibody&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN in the presence of hepatic metastasis)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Prior malignancy allowed provided the treating physician determines that the patient's&#xD;
             life expectancy is best defined by diagnosis of non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 by NCI CTCAE v. 3.0&#xD;
&#xD;
          -  No prior severe allergic reaction to any of the following:&#xD;
&#xD;
               -  Carboplatin&#xD;
&#xD;
               -  Taxane therapy&#xD;
&#xD;
               -  Monoclonal antibody&#xD;
&#xD;
               -  Hypersensitivity (NCI CTCAE grade3-4) to a drug formulated in Cremophor® EL&#xD;
                  (polyoxyethylated castor oil)&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No significant history of uncontrolled cardiac disease including, but not limited to,&#xD;
             any of the following:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Uncontrolled congestive heart failure&#xD;
&#xD;
               -  Cardiomyopathy with decreased ejection fraction&#xD;
&#xD;
          -  No underlying interstitial lung disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior and no concurrent therapeutic radiotherapy&#xD;
&#xD;
               -  Palliative radiotherapy for painful bone lesions allowed&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy&#xD;
&#xD;
          -  No investigational agent(s) within the past 30 days&#xD;
&#xD;
          -  Not requiring concurrent treatment with any of the following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Amprenavir&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
          -  No other concurrent chemotherapy or cetuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E. Stinchcombe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 17, 2009</study_first_submitted>
  <study_first_submitted_qc>October 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

